Medtronic ($MDT) podcast mentions
Per Ticker.id: 14 Medtronic ($MDT) mentions across 6 podcasts (30 days) — timestamped, verifiable quotes, updated 2026-10-02.
Absolutely. So I spent my career really on the commercial and operational side of neuroscience, a lot of time at Medtronic, over 8 years there, 3+ years at GE Healthcare, and now the last 2 years at Insightec. So I lead our current global commercial organization, which includes sales, marketing, market access, medical affairs, really our full go-to-market engine for what we're doing to drive, uh, Focus Ultrasound to become the standard of care. My job is pretty exciting right now. Um, we get a chance to do a lot of unique things with the cutting-edge technology. And really what motivates me and drives me and why I came over to Insightec and really am fascinated with the neuroscience side of the business is that you have this opportunity to take great technology and bring into the hands of amazing clinicians. But really all that only matters is if you can provide access to patients and get it into the right markets.
Jake Ganim · Becker’s Healthcare Podcast · Why Health Systems Should Be Thinking About MR-Guided Focused Ultrasound Right Now · 2026-10-02Um, the stock I was wondering about is Medtronic PLC, MDT.
Speaker D · Mad Money w/ Jim Cramer · Mad Money w/ Jim Cramer 10/1/26 · 2026-10-01Okay, now, you know, I am so glad you brought this stock up. I'm going to tell you what, this is, this is why my job's hard. Medtronic had a great quarter. Jeff Martha is doing a fantastic job. I thought they put everything together. They're even getting rid of the commodities stuff. And what happens? Stock goes up and then goes back down. That's why this market is so daunting. I like Medtronic, but I gotta tell you, at 14 times earnings, I don't know what supports it. I buy a little and then wait a little more till it goes down. Darn, it should be higher, but I can't make it go higher. In the third quarter, Software finally bounced back. I'm curious to see what happens this quarter when we see what companies are saying about higher rates. On MidMoney Tonight, can McDonald's finally deliver the turnaround it desperately needs? I'm going to take a closer look at the stock. Then, as the AI trade shifts, we've seen a quiet rally in one key area of the market. Don't miss my deep dive on the stocks that go— that keep the internet going.
Jim Cramer · Mad Money w/ Jim Cramer · Mad Money w/ Jim Cramer 10/1/26 · 2026-10-01I would really appreciate if you could give me an entry point for a company called Medtronic, MDT.
Steve Peasley · InvestTalk · The Lifemaxxing Trap: Why 72% of Americans Are Risking Their Financial Future · 2026-09-29Now, normally we do a listener question at the end of the show. But today, we got a pretty meaty question here. So I wanted to give us a little bit of extra time to discuss it. Remember, if you have a question, go ahead and email us at podcasts@fool.com. That's podcasts with an S. We have also got the email in the show show description in case you need it there. Today's question comes in from Zach. Guys, I'm going to split it up because it's a meaty question, several questions, and I thought it was worth diving into. "Hi, Motley Fool team. Longtime listener and love the show. With Medtronic recently launching a voluntary exchange offer to separate its diabetes business, MiniMed, I have been thinking about how everyday investors should evaluate these types of corporate actions. Since you provide great high-level educational Her perspective's in the mailbag. Thanks, Zach. Could you break down how splits and exchange offers work? And we'll start with this first question that he wants specifically.
Tyler Crowe · Motley Fool Hidden Gems Investing · Oracle Calls Force Majeure Already? · 2026-09-24The dividend investor dilemma: how should income-focused investors weigh keeping an established dividend payer versus swapping for a fast-growing non-dividend pure play, even with a built-in incentive? And in this case, for the mini Medtronic, MiniMed thing, there's a 7% valuation discount that you get as an investor as part of the spinoff. So guys, a dividend investor getting a non-dividend stock in an exchange? How does this work? What are your thoughts?
Tyler Crowe · Motley Fool Hidden Gems Investing · Oracle Calls Force Majeure Already? · 2026-09-24Zach tipped the scales for me in how he worded the question. He said, "How should an income-focused investor—" Again, I don't know Zach. I can tell you, though, how I would think about this. If I bought Medtronic for the dividend, if I'm focused on income, I'm probably keeping the income. I'm going to be more swayed by keeping Medtronic and keeping the dividend. The great thing about this— he also asks, "How do split-offs and exchanges work?" It's basically a tax-free— sometimes you get both, sometimes you have to choose one or the other, like in this case. But it's a tax-free carving up of the company. Here's the great thing. You can have both. You can keep your Medtronic and buy the other company, MiniMed. Buy shares for the same tax implications, if you want. So, you don't have to choose. Your choice would be, you have to commit new capital. But look, if you are an income-focused investor, and that's the reason you bought a dividend stock, I think if it was me, I'd probably lean towards keeping the dividend stock.
Lou Whitman · Motley Fool Hidden Gems Investing · Oracle Calls Force Majeure Already? · 2026-09-24If you're focused on growth and you bought Medtronic because you were excited about the growth, then probably the dividend means less to you and maybe you look at the other one.
Lou Whitman · Motley Fool Hidden Gems Investing · Oracle Calls Force Majeure Already? · 2026-09-24Now, it could be because Medtronic is a dividend player, they think their investment base is less interested in growth, so they're just trying to even the playing fields that way with their target audience. Or, it could be a signal that the market is probably favoring Medtronic. I, you know, it's, again, it's hard to just give one-size-fits-all answers here, but I do think you have to read the individual situation and kind of figure out, like, what are the, what are the signals telling you? Like, if I'm playing poker with Medtronic here, what is the tell here? What are they telling me that they're not telling me that I can use to make a decision?
Lou Whitman · Motley Fool Hidden Gems Investing · Oracle Calls Force Majeure Already? · 2026-09-24Yeah, I, I like this move as far as splitting out MiniMed from Medtronic. I think it was a good move. When you talk about the difference of the growth rates, it's not that different. I mean, MiniMed is better, but it's not drastically in another category of growth level. It's, it's, you know, mid-single digits and high single digits. It's not that huge of a difference, but the profit margin difference is quite significant. And so it does make sense to me for Medtronic to to spin out MiniMed and then be able to dedicate its own capital to growing its higher margin business. That to me is going to potentially grow profits faster at Medtronic than what the profits are gonna grow at MiniMed. So it makes a lot of sense to me that it would make this move. But stop me if you've heard this one before.
Jon Quast · Motley Fool Hidden Gems Investing · Oracle Calls Force Majeure Already? · 2026-09-24We looked into this story, the weight loss drug boom hits its middle age, what the GLP-1 economy means for your portfolio. We also answered listener questions on Medtronic. And if you happen to miss it, go check it out. Best way to get your every show is to follow Invest Talk wherever you get your podcasts. Now we have a lot of ground to cover today over the next 45 minutes or so, and our main focus point is about how investors are borrowing about one— nearly $1.5 trillion to buy stocks. That's margin debt. Is this a warning or is it just noise? Climbed $37 billion in August to $1.45 trillion, the second highest reading on record. The number has gone up 140% since the end of 2022 while the S&P has gained 98%. So we'll break down this leverage and roughly what 4.5% of GDP actually tells investors about market risk.
Justin Klein · InvestTalk · Investors Borrowed $1.45 Trillion to Buy Stocks: Is Record Margin Debt a Warning or Just Noise? · 2026-09-23Yeah, hey Luke, thanks for taking my call. As always, really appreciate everything you guys do. Um, yeah, calling about Medtronic and their, uh, MiniMed exchange that they're offering at a 7% discount. I know you guys did hold, uh, MDT in some of your accounts. I was just curious, um, what you guys are considering doing with that offer.
Speaker E · InvestTalk · The Weight-Loss Drug Boom Hits Its Middle Age: What the GLP-1 Economy Means for Your Portfolio · 2026-09-23Sure, that is a great question. We actually were, uh, taking a look at that today. For those who don't know, Medtronic is a name that we do still hold for our clients in a couple of our strategies. It is one of those global leaders in healthcare technology. They have really expanded more recently in their heart segment, and it's done certainly a decent compared to the industry, right? It's still down about 5.5% year-to-date. It's outperforming healthcare by about 2.8%. Now, for this MiniMed exchange offer, what is happening is Medtronic is spinning off its diabetes business, MiniMed, into ticker MMED as a separate public company. So you can exchange your MDT shares at about a 7% discount, meaning you're getting essentially $1.07 worth of MiniMed for every dollar of Medtronic that you tender.
Luke Guerrero · InvestTalk · The Weight-Loss Drug Boom Hits Its Middle Age: What the GLP-1 Economy Means for Your Portfolio · 2026-09-23It is, uh, something that was launched in September So there's gonna be up to 225 newly issued MiniMed shares. And generally speaking, it is, it is tax-free, uh, for US federal income tax purposes when you do this type of exchange. The reason why they're doing this, and I, I, from a shareholder of Medtronic perspective, I like it, is because the diabetes business has really been a drag on the company. And so Medtronic essentially wants to spin off that, that poor segment and focus more on what's been really strong— cardiovascular, surgical robotics, and neuroscience as well. Now, it's difficult because you're looking at this on its face, and it is moving part of its business that is not doing well. And that's why they are trying to entice shareholders with this type of discount. You immediately get, uh, you know, 7% discount.
Luke Guerrero · InvestTalk · The Weight-Loss Drug Boom Hits Its Middle Age: What the GLP-1 Economy Means for Your Portfolio · 2026-09-23So if you believe that the diabetes insulin pump market has long-term growth, This is a bit more of a focused way to do it. I would say if you— it kind of depends why you're invested in this name, right? If you believe that the company is going to be better off without it, that's kind of one of the reasons why you would want to hold on to Medtronic. We haven't fully made a decision here yet, but on its face, a discount like this exists because there is risk. So are they compensating you enough for the risk that you're taking on from this spinoff? We are still doing some analysis. Uh, certainly, uh, you know, this doesn't happen too often, uh, with individual companies that you hold. So it does present a bit of an interesting situation. So for us, haven't made a decision yet, but hopefully that provides you some context with what's going on here and what the real risks might be. Thanks for the call, Chris.
Luke Guerrero · InvestTalk · The Weight-Loss Drug Boom Hits Its Middle Age: What the GLP-1 Economy Means for Your Portfolio · 2026-09-23